Viking Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine diseases. Its pipeline includes VK2809, a thyroid hormone receptor beta agonist in Phase IIb testing for liver disease; VK5211, an androgen receptor modulator in Phase II for hip fracture recovery; VK0612 in Phase II for metabolic disorders and anemia; VK2735, a dual glucagon-like peptide 1 agonist in early-stage trials; and VK0214 for X-linked adrenoleukodystrophy. The company was founded in 2012 and operates from San Diego.

entry readiness 80 · GOOD SETUP · exit proximity 0

Value area 29.04–35.60 · 92% of 120d volume overhead · heavy supply